Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Status:
Completed
Trial end date:
2017-12-31
Target enrollment:
Participant gender:
Summary
The (Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial)
CABANA Trial has the overall goal of establishing the appropriate roles for medical and
ablative intervention for atrial fibrillation (AF). The CABANA Trial is designed to test the
hypothesis that the treatment strategy of left atrial catheter ablation for the purpose of
eliminating atrial fibrillation (AF) will be superior to current state-of-the-art therapy
with either rate control or rhythm control drugs for decreasing the incidence of the
composite endpoint of total mortality, disabling stroke, serious bleeding, or cardiac arrest
in patients with untreated or incompletely treated AF.
Phase:
N/A
Details
Lead Sponsor:
Mayo Clinic
Collaborators:
Abbott Medical Devices Biosense Webster, Inc. National Heart, Lung, and Blood Institute (NHLBI) St. Jude Medical